- Kenneth L. Londoner, chairman and CEO of BSGM, said in a news release that interns will be offered a ‘360-degree overview’ of the business within an entrepreneurial environment
- Firm is a development stage medical device company with products that assist electrophysiologists; it is also assembling a portfolio of software tools for arrhythmia treatments
- BioSig values global electrophysiology (EP) market at $4.6 billion, with research firm projecting that market will reach $4.73 billion by 2019
- BioSig recently named first two members to new advisory board
BioSig Technologies, Inc. (OTCQB: BSGM) will be offering summer internships to Bates College students in 2018 as part of that school’s Purposeful Work initiative. Bates, based in Lewiston, Maine, has an internship component as part of that program. The Bates interns at BioSig will be compensated, the company announced (http://ibn.fm/EGmQK). Core employers in the 2017 Bates Purposeful Work program included Oppenheimer Co. in Boston; Memorial Sloan Kettering Cancer Center in New York; L.L. Bean, Inc. in Maine; and the American Chamber of Commerce in China.
In a news release, Kenneth L. Londoner, chairman and CEO of BSGM, said, “We were impressed with the consistent commitment to excellence that Bates demonstrates, and we are confident that our partnership will allow us to take both of our programs to the next level.” He added that the interns would be given a ‘360-degree overview’ of the business.
BioSig is a Santa Monica, California-based, development stage medical device company with an office in Austin, Texas. The company is developing a proprietary biomedical signal-processing platform and is preparing to commercialize its Precise Uninterrupted Real-time evaluation of Electrograms, or PURE EP™ System. In its spring 2018 corporate presentation, BioSig valued the electrophysiology marketplace at $4.6 billion (http://ibn.fm/912BY), while research firm Markets and Markets projects that the marketplace will reach $4.73 billion by 2019, growing at a CAGR of 10.3 percent from 2014-2019 (http://ibn.fm/ViYSt).
PURE EP is a unique cardiac signal acquisition and display system engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig is also assembling a portfolio of software tools designed for electrophysiologists and arrhythmia treatments.
BioSig also recently announced the formation of an advisory board to help in such areas as partnerships, government affairs, intellectual property and capital markets, and it named the first two members, Kent Bennett Williams, CEO and principal of Vista Asset Management, LLC, and Dr. Ramachandra Malya, M.D., a medical director and nephrologist (http://ibn.fm/ZNmax). In announcing the additions, Londoner stated, “We wanted to appoint a proactive Advisory Board, which brings fresh thinking, skills and expertise to enhance our company’s performance. Kent and Dr. Malya bring impressive career achievements, which will deliver immediate impact in the top priority areas of our business.”
For more information, visit the company’s website at www.BioSigTech.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
